Objective  To explore the clinical efficacy of ABC-X model intervention  combined with omalizumab on moderate to severe allergic asthma (AA) and negative emotions of family members.  Methods  AA children and their families from the First Affiliated Hospital of Xinjiang Medical University from January 2022 to January 2023 were prospectively recruited in the research. According to the random number table method, AA children and their families were divided into ABC-X group (ABC-X model care intervention combined with omalizumab) and routine group (usual care combined with omalizumab). Observe and compare clinical efficacy before and after intervention, incidence of adverse reactions to omalizumab, pulmonary function, immune function, inflammatory indicators, and negative emotions of family members.

Results  A total of 120 children with asthma and their families were recruited in  the study, with 60 pairs in each group. Before the intervention, C-ACT scores, lung function, immune function, inflammatory indicators, SAS scores and SDS scores showed no statistically significant differences between the ABC-X and conventional groups (P>0.05). After 16 weeks of intervention, in terms of clinical efficacy and safety in children with AA, the total response rate and C-ACT rate in the ABC-X group were significantly higher than the conventional group after intervention (P<0.05), and the occurrence of adverse reactions were similar in both groups (P>0.05). In terms of family negative emotions, SAS and SDS scores decreased significantly compared with before intervention (P<0.05), and SAS and SDS scores in the ABC-X group were significantly lower than the conventional group after intervention after intervention (P<0.05). In terms of lung function and immune function, FEV₁, FEV₁/FVC, PEF, CD3, CD4 and CD4/CD8 were significantly higher than before intervention (P<0.05), and FEV₁, FEV₁/FVC, PEF, CD3, CD4 and CD4/CD8 were significantly higher than the conventional group (P<0.05). In terms of inflammatory indicators, MIP-1α, MCP-1, IL-1β and IL-8 were significantly decreased (P<0.05), and MIP-1α, MCP-1, IL-1β and IL-8 in the ABC-X group were significantly lower than those in the conventional group after intervention (P<0.05).

Conclusion  ABC-X model nursing intervention can promote the effect of omalizumab, improve lung function and immune function, enhance anti-inflammatory effect in children with moderate to severe AA.

1.王薇, 何志伟, 范彦博, 等. 咳喘凝胶贴膏穴位敷贴对支气管哮喘大鼠炎症因子的影响[J]. 中国药师, 2022, 25(5): 812-815. [Wang W, He ZW, Fan YB, et al. Effect of acupoint application of Kechuan gel plaster on inflammatory factors in bronchial asthma rats[J]. China Pharmacist, 2022, 25(5): 812-815.] DOI: 10.19962/j.cnki. issn1008-049X.2022.05.010.

2.Bateman ED, Hurd SS, Barnes PH, et al. Global strategy for asthma management and prevention: GINA executive summary[J]. Eur Respir J, 2008, 31(1): 143-178. DOI: 10.1183/09031936.00138707.

3.陈慧, 付白娣. 个体化系统干预对儿童支气管哮喘雾化吸入的影响[J]. 中国妇幼保健, 2017, 32(23): 5921-5923. [Chen H, Fu BD. The effect of individualized system intervention on nebulized inhalation in children with bronchial asthma[J]. Maternal and Child Health Care of China, 2017, 32(23): 5921-5923.] DOI: 10.7620/zgfybj.j.issn.1001-4411.2017.23.42.

4.涂彩霞, 李惠英, 张泉, 等. FCER2(rs28364072)多态性对吸入用布地奈德治疗儿童哮喘疗效的影 响 [J]. 药物流行病学杂志, 2022, 31(6): 395-399. [Tu CX, Li  HY, Zhang Q, et al. The effect of FCER2(rs28364072) polymorphism on the efficacy of inhaled budesonide in the treatment of childhood asthma[J]. Journal of Pharmacoepidemiology, 2022, 31(6): 395-399.]DOI: 10.19960/j.cnki.issn1005-0698.2022.06.006.

5.杨柳, 王亚利, 郑良霞, 等. 基于医护一体化的教育与管理提高支气管哮喘控制: 一项真实世界的前瞻性队列研究[J]. 中国循证医学杂志, 2022, 22(2): 140-147. [Yang L, Wang YL, Zheng LX, et al. Improving bronchial asthma control through integrated education and management based on healthcare: a real-world prospective cohort study[J]. Chinese Journal of Evidence-Based Medicine, 2022, 22(2): 140-147.] DOI: 10.7507/1672-2531.202109013.

6.Sztafińska A, Gwardys M, Podlecka D, et al. Effectiveness of omalizumab in children and adolescents with uncontrolled allergic asthma: a case series from Poland[J]. Postepy Dermatol Alergol, 2021, 38(3): 427-432. DOI: 10.5114/ada.2021.107929.

7.邹培远, 黄灵敏, 李波, 等. 贵阳市0~14岁儿童哮喘流行病学初筛调查结果分析[J]. 贵州医科大学学报, 2018, 43(4): 436-440. [Zou PY, Huang LM, Li B, et al. Analysis of epidemiological preliminary screening survey results on asthma in children aged 0-14 in Guiyang city[J]. Journal of Guizhou Medical University, 2018, 43(4): 436-440.] DOI: 10.19367/j.cnki.1000-2707.2018.04.013.

8.Cheng L, Yang T, Ma X, et al. Effectiveness and safety studies of omalizumab in children and adolescents with moderate-to-severe asthma[J]. J Pharm Pract, 2023, 36(2): 370-382. DOI: 10.1177/08971900211038251.

9.国家呼吸系统疾病临床医学研究中心, 中华医学会儿科学分会呼吸学组哮喘协作组, 中国医药教育协会儿科专业委员会, 等. 奥马珠单抗在儿童过敏性哮喘临床应用专家共识[J]. 中华实用儿科临床杂志, 2021, 36(12): 881-890.[National Clinical Medical Research Center for Respiratory Diseases, Asthma Collaborative Group of Respiratory Science Branch of Chinese Medical Association, Pediatric Professional Committee of China Medical Education Association, et al. Expert consensus on the clinical application of omazumab in pediatric allergic asthma[J]. Chinese Journal of Applied Clinical Pediatrics, 2021, 36(12): 881-890.] DOI: 10.3760/cma.j.cn101070-20210531-00621.

10.皇惠杰, 向莉, 侯晓玲, 等. 奥马珠单抗治疗儿童过敏性哮喘的临床疗效观察[J]. 北京医学, 2023, 45(1): 47-51.[ Huang HJ, Xiang L, Hou XL, et al. Clinical efficacy observation of omazumab in the treatment of allergic asthma in children[J]. Beijing Medical Journal, 2023, 45(1): 47-51.] DOI: 10.15932/j.0253-9713.2023.01.010.

11.张骞, 侯瑞霞, 张超, 等. 奥马珠单抗联合布地奈德福莫特罗粉吸入剂治疗中、重度过敏性哮喘患儿的临床研究[J]. 中国临床药理学杂志, 2021, 37(19): 2577-2580. [Zhang Q, Hou RX, Zhang C, et al. A clinical study on the combination of omazumab and budesonide fomotro powder inhalation in the treatment of children with moderate to severe allergic asthma[J]. Chinese Journal of Clinical Pharmacology, 2021, 37(19): 2577-2580.] DOI: 10.13699/j.cnki.1001-6821.2021.19.008.

12.孔祥欣. 认知干预在抗结核药物致肝损伤患者中的应用效果[J]. 中国当代医药, 2022, 29(23): 64-67. [Kong XX. The application effect of cognitive intervention in patients with liver injury caused by anti tuberculosis drugs[J]. China Modern Medicine, 2022, 29(23): 64-67] DOI: 10.3969/j.issn.1674-4721.2022.23.017.

13.侯晓梅. ABC-X理论模型干预对重症肺炎患儿家属疾病不确定感及心理状态的影响[J]. 中国健康心理学杂志, 2021, 29(4): 523-528. [Hou XM. The impact of ABC-X theoretical model intervention on the uncertainty and psychological state of family members of children with severe pneumonia[J]. Chinese Journal of Health Psychology, 2021, 29(4): 523-528.] DOI: 10.13342/j.cnki. cjhp.2021.04.010.

14.Chalia M, Lee CW, Dempsey LA, et al. Hwmodynamic response to burst-suppressed and discontinous electroencephalography activity in infants with hypoxic ischemic encephalopathy[J]. Neurophotonics, 2016, 3(3): 031408. DOI: 10.1117/1.NPh.3.3.031408.

15.周赛赛, 朱火梅, 陈思超. 基于ABC-X模型的围生期管理对初产妇负性情绪应对方式及生活质量的影响[J]. 中国妇幼保健, 2023, 38(15): 2730-2734. [Zhou SS, Zhu HM, Chen SC. The impact of perinatal management based on the ABC-X model on the negative emotional coping styles and quality of life of primiparous women[J]. Maternal and Child Health Care of China, 2023, 38(15): 2730-2734.] DOI: 10.19829/j.zgfybj.issn.1001-4411.2023.15.004.

16.李丽, 张秀秀, 巴蕊. ABC-X模型在改善结肠癌负性情绪和生活质量中的应用效果分析[J]. 实用中医内科杂志, 2022, 36(3): 141-143. [Li L, Zhang XX, Ba R. Analysis of the application effect of ABC-X model in improving negative emotions and quality of life in colon cancer[J]. Journal of Practical Traditional Chinese Internal Medicine, 2022, 36(3): 141-143.] DOI: 10.13729/j. issn.1671-7813. Z20211421.

17.侯晓梅. ABC-X理论模型干预对重症肺炎患儿家属疾病不确定感及心理状态的影响[J]. 中国健康心理学杂志, 2021, 29(4): 523-528. [Hou XM. The impact of ABC-X theoretical model intervention on the uncertainty and psychological state of family members of children with severe pneumonia[J]. Chinese Journal of Health Psychology, 2021, 29(4): 523-528.] DOI: 10.13342/j. cnki. cjhp.2021.04.010.

18.中华医学会儿科学分会呼吸学组, 《中华儿科杂志》编辑委员会. 儿童支气管哮喘诊断与防治指南(2016年版)[J]. 中华儿科杂志, 2016, 54(3): 167-181. [Respiratory Science Branch of Chinese Medical Association, Chinese Journal of Pediatrics Editorial Committee. Guidelines for the diagnosis, prevention and treatment of bronchial asthma in children (2016 edition)[J]. Chinese Journal of Pediatrics, 2016, 54(3): 167-181.] DOI: 10.3760/cma.j.issn.0578-1310.2016.03.003.

19.Voorend-van Bergen S, Vaessen-Verberne AA, de Jongste JC, et al. Asthma control questionnaires in the management of asthma in children: a review[J]. Pediatr Pulmonol, 2015, 50: 202-208. DOI: 10.1002/ppul.23098.

20.王莉，王小军. TH17细胞平衡及免疫微环境在过敏性哮喘发病中的作用[J]. 中华肺部疾病杂志(电子版), 2020, 13(5): 648-652. [Wang L, Wang XJ. The role of TH17cell balance and immune microenvironment in the pathogenesis of allergic asthma[J]. Chinese Journal of  Lung Diseases (Electronic Edition), 2020, 13(5): 648-652.] DOI: 10.3877/cma.j.issn.1674-6902.2020.05.014.

21.李建英, 刘毅, 罗岚, 等. 奥马珠单抗治疗中重度过敏性哮喘的临床效果及安全性研究[J]. 中国医药, 2022, 17(11): 1638-1642. [Li JY, Liu Y, Luo L, et al. Clinical efficacy and safety study of omazumab in the treatment of moderate to severe allergic asthma[J]. Chinese Medicine, 2022, 17(11): 1638-1642.] DOI: 10.3760/j.issn.1673-4777.2022.11.009.